This translated to a positive SSTR2A status in 12 IDH-wildtype glioblastomas (13%), 5 IDH-wildtype astrocytomas (23%), 10 IDH-mutant astrocytomas (27%), and 15 IDH-mutant and 1p/19q-codeleted oligodendrogliomas (79%) demonstrating a significant association between SSTR2A status (positive or negative) and glioma type (p < 0.001, Fisher's exact test). This evidence concerns the gene IDH2 and central nervous system cancer.